MILWAUKEE – The Society for Clinical Data Management announced that is has recently certified its 500th Certified Clinical Data Manager (CCDM).
The CCDM credential is an elite mark of excellence in and commitment to clinical data management. Approximately 160 CCDMs were certified in 2009, nearly 40% of whom live outside North America.
“The CCDM designation is recognized globally as a standard for quality data management staff,” said 2010 SCDM Chair Ralph J. Russo, CCDM. “It provides the clinical research industry with a measure of expertise.”
Since its inception in 2005, the Certified Clinical Data Manager program has enhanced the quality and professionalism of CDMs worldwide. To earn the CCDM credential, candidates must first meet minimum standards of education and experience, then pass a challenging exam testing knowledge of best practices in all areas of clinical data management. Once obtained, certification must be renewed every three years by completing education activities or retaking the exam.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.